Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.57 |
| ▸ | RAB9A | P51151 | 7/20 | 0.57 |
| ▸ | NPC1 | O15118 | 5/20 | 0.57 |
| ▸ | MAPT | P10636 | 3/20 | 0.57 |
| ▸ | ATM | Q13315 | 1/20 | 0.57 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 3/20 | 0.54 |
| ▸ | CCR1 | P32246 | 2/20 | 0.54 |
| ▸ | CCR5 | P51681 | 2/20 | 0.54 |
| ▸ | CCR8 | P51685 | 2/20 | 0.54 |
| ▸ | METAP1 | P53582 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | BLM | P54132 | 1/20 | 0.54 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.54 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.54 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.54 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.52 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 4/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fluoride SCHEMBL27903468 | 0.98 | KDM4E (0.55) | KDM4ERAB9ANPC1MAPTATM | |
| Ammonia Solution, Strong SCHEMBL28442530 | 0.98 | KDM4E (0.55) | KDM4ERAB9ANPC1MAPTATM | |
| Urea SCHEMBL21777343 | 0.89 | KDM4E (0.47) | KDM4ERAB9ANPC1MAPTATM | |
| Carbamic Acid SCHEMBL10365602 | 0.88 | PDPK1 (0.50) | KDM4ERAB9ANPC1MAPTATM | |
| SCHEMBL30511083 | 0.84 | — | — | |
| SCHEMBL4902877 | 0.80 | RAB9A (0.61) | KDM4ERAB9AMAPTPDPK1LMNA | |
| SCHEMBL4026612 | 0.80 | PDPK1 (0.46) | KDM4ERAB9ANPC1MAPTATM | |
| SCHEMBL28064040 | 0.79 | PDPK1 (0.49) | KDM4ERAB9ANPC1MAPTATM | |
| SCHEMBL2730329 | 0.76 | RAB9A (0.53) | KDM4ERAB9APDPK1LMNACCR1 | |
| SCHEMBL26259375 | 0.76 | PDPK1 (0.59) | KDM4ERAB9ANPC1MAPTPDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 386 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122078029-A | Wear-resistant ultraviolet-aging-resistant glass fiber silicon core composite board and preparation method thereof | — | 2026-05-26 | — | — | CN | claimed |
| EP-3843845-B1 | INHIBITION OF PROTEIN KINASES TO TREAT FRIEDREICH ATAXIA | UNIV MASSACHUSETTS (US) | 2026-03-11 | — | — | EP | claimed |
| US-12281308-B2 | Inhibition of protein kinases to treat Friedreich ataxia | UNIVERSITY OF MASSACHUSETTS (US) | 2025-04-22 | — | — | US | claimed |
| CN-118406092-A | Multi-tooth chelate nickel catalyst and application thereof in preparation of ethylene-alpha-olefin copolymer | 浙江大学 | 2024-07-30 | — | — | CN | claimed |
| CN-114591354-B | Production and preparation method of 4-hydroxy-1, 5-naphthyridine europium complex | 兰州睿尔思新材料有限公司 | 2023-11-24 | — | — | CN | claimed |
| CN-113149980-A | Tert-butyloxycarbonyl micromolecule organic compound targeting PUF60, derivative thereof and application thereof | 上海市奉贤区中心医院 | 2021-07-23 | — | — | CN | claimed |
| EP-3055301-B1 | (2-(5-ISOINDOLIN-2-YL)PYRIMIDIN-4-YL)-AMINE DERIVATIVES AS RHO KINASE INHIBITORS FOR TREATING AUTOIMMUNE DISEASES | KADMON CORP LLC (US) | 2019-11-20 | — | — | EP | claimed |
| US-10125144-B2 | Rho kinase inhibitors | KADMON CORPORATION, LLC (US) | 2018-11-13 | — | — | US | claimed |
| US-20160237095-A1 | RHO KINASE INHIBITORS | KADMON CORPORATION, LLC | 2016-08-18 | — | — | US | claimed |
| CN-105658059-A | Pesticidal compositions and related methods | 美国陶氏益农公司 | 2016-06-08 | — | — | CN | claimed |
| EP-0828738-B1 | PYRIDYL-THIAZOLES AND THEIR USE TO PROTECT PLANTS AGAINST INFECTIONS BY MICRO-ORGANISMS | BAYER CROPSCIENCE AG (DE) | 2003-12-17 | — | — | EP | claimed |
| CN-1065242-C | Pyridyl-thiazoles | BAYER AG (DE) | 2001-05-02 | — | — | CN | claimed |
| US-5945380-A | FUNGICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1999-08-31 | — | — | US | claimed |
| EP-0680967-B1 | Erythromycin derivatives, their process of preparation and their use as medicaments | HOECHST MARION ROUSSEL INC (FR) | 1998-10-14 | — | — | EP | claimed |
| CN-1190969-A | Pyridyl-thiazoles | BAYER AG (DE) | 1998-08-19 | — | — | CN | claimed |
| EP-0828738-A1 | PYRIDYL-THIAZOLES AND THEIR USE TO PROTECT PLANTS AGAINST INFECTIONS BY MICRO-ORGANISMS | BAYER AG (DE) | 1998-03-18 | — | — | EP | claimed |
| WO-1996037493-A1 | PYRIDYL-THIAZOLES AND THEIR USE TO PROTECT PLANTS AGAINST INFECTIONS BY MICRO-ORGANISMS | BAYER AKTIENGESELLSCHAFT (DE) | 1996-11-28 | — | — | WO | claimed |
| US-5470862-A | Intravenous anesthetics | OHMEDA PHARMACEUTICAL PRODUCTS DIVISION INC. (US) | 1995-11-28 | — | — | US | claimed |
| WO-1995029929-A1 | NOVEL ERYTHROMYCIN DERIVATIVES, METHOD FOR THEIR PREPARATION AND THEIR USE AS DRUGS | ROUSSEL UCLAF (FR) | 1995-11-09 | — | — | WO | claimed |
| EP-0680967-A1 | Erythromycin derivatives, their process of preparation and their use as medicaments | ROUSSEL-UCLAF (FR) | 1995-11-08 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160237095-A1 | RHO KINASE INHIBITORS | ROCK2, ROCK1, RHOA | KDM4E 1873/4885RAB9A 209/4885NPC1 804/4885 |
| US-10125144-B2 | Rho kinase inhibitors | ROCK2, ROCK1, RHOA | KDM4E 1873/4885RAB9A 209/4885NPC1 804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.